

Date of last issue: 30.09.2023

Timolol Formulation

Version

Revision Date:

	25.01.2024	159	S Number: 18363-00015	Date of first is	sue: 01.05.2017
ction 1:	Identification				
Produ	ct name	:	Timolol Formula	ation	
	facturer or supplier's d	etai			
Comp	any	:	MSD		
Addre	SS	:	33 Whakatiki St Upper Hutt - Ne	reet - Private Ba w Zealand	g 908
Telepl	hone	:	0800 800 543		
Emerç	gency telephone number	:	0800 764 766 (CHEMCALL)	0800 POISON)	0800 243 622 (0800
E-mai	l address	:	EHSDATASTE	NARD@msd.co	m
Reco	mmended use of the ch	em	ical and restrict	ions on use	
	nmended use	:	Pharmaceutical		
Restri	ctions on use		Not applicable		
	Classification ductive toxicity	:	Category 2		
Repro Specif			0,	rdio-vascular sys	stem, Lungs)
Repro Specil repea	ductive toxicity fic target organ toxicity -		0,	rdio-vascular sys	stem, Lungs)
Repro Specif repeat	ductive toxicity fic target organ toxicity - ted exposure		0,	rdio-vascular sys	stem, Lungs)
Repro Specif repea GHS I	ductive toxicity fic target organ toxicity - ted exposure abel elements rd pictograms		0,	rdio-vascular sys	stem, Lungs)
Repro Specif repea GHS I Hazar Signa	ductive toxicity fic target organ toxicity - ted exposure abel elements rd pictograms		Category 1 (Ca Category 1 (Ca Danger H361d Suspect H372 Causes d	ed of damaging famage to organs	the unborn child. s (Cardio-vascular system, beated exposure.

SDS Number:



Timolol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	25.01.2024	1598363-00015	Date of first issue: 01.05.2017

P264 Wash skin thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
	26921-17-5	>= 0.1 -< 1
morpholino-1,2,5-thiadiazole monomaleate		

Section 4: First-aid measures

General advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed Protection of first-aiders	:	Suspected of damaging the unborn child. Causes damage to organs through prolonged or repeated exposure. First Aid responders should pay attention to self-protection,



Timolol Formulation

Version 4.2	Revision Date: 25.01.2024		98363-00015	Date of last issue: 30.09.2023 Date of first issue: 01.05.2017			
Note	es to physician	:	when the potentia	nmended personal protective equipment I for exposure exists (see section 8). cally and supportively.			
Section	5: Fire-fighting measure	S					
Suita	able extinguishing media	:	Water spray Alcohol-resistant f Carbon dioxide (C Dry chemical				
Uns med	uitable extinguishing ia	:	None known.				
Spec fight	cific hazards during fire-	:	Exposure to comb	bustion products may be a hazard to health.			
	ardous combustion prod-	:	Carbon oxides Metal oxides Phosphorus comp	ounds			
Spec ods	Specific extinguishing meth- ods		Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to c so. Evacuate area.				
	cial protective equipment refighters	:	In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.				
Section	6: Accidental release me	easi	ures				
tive	sonal precautions, protec- equipment and emer- cy procedures	:		ective equipment. ing advice (see section 7) and personal pro- recommendations (see section 8).			
Envi	ronmental precautions	:	Prevent spreading barriers). Retain and dispos	akage or spillage if safe to do so. g over a wide area (e.g. by containment or oil e of contaminated wash water. should be advised if significant spillages			
	nods and materials for ainment and cleaning up	:	For large spills, pument to keep mat be pumped, store Clean up remaining bent. Local or national uposal of this mate employed in the comine which regula Sections 13 and 1	absorbent material. ovide dyking or other appropriate contain- erial from spreading. If dyked material can recovered material in appropriate container. og materials from spill with suitable absor- egulations may apply to releases and dis- rial, as well as those materials and items leanup of releases. You will need to deter- tions are applicable. 5 of this SDS provide information regarding tional requirements.			



Timolol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	25.01.2024	1598363-00015	Date of first issue: 01.05.2017

Section 7: Handling and storage

Technical measures	See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.	
Local/Total ventilation Advice on safe handling	Use only with adequate ventilation. Do not breathe mist or vapours. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as- sessment Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.	
Hygiene measures	If exposure to chemical is likely during typical use, provide ey flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.	e
Conditions for safe storage	Keep in properly labelled containers. Store in accordance with the particular national regulations.	
Materials to avoid	Do not store with the following product types: Strong oxidizing agents	

Section 8: Exposure controls/personal protection

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis	
(S)-3-[3-(tert-butylamino)-2- hydroxypropoxy]-4- morpholino-1,2,5-thiadiazole monomaleate	26921-17-5	TWA	10 µg/m3 (OEB 3)	Internal	
	Further information: Eye, Skin				
		Wipe limit	100 µg/100 cm ²	Internal	

Engineering measures

: Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., dripless quick connections). All engineering controls should be implemented by facility



Timolol Formulation

ersion .2	Revision Date: 25.01.2024		OS Number: 98363-00015	Date of last issue: 30.09.2023 Date of first issue: 01.05.2017
			protect products, Containment tech are required to co	
Perso	onal protective equip	ment		
·	iratory protection	:	 If adequate local exhaust ventilation is not available o sure assessment demonstrates exposures outside the ommended guidelines, use respiratory protection. 	
	lter type protection	•	Particulates type	
Ma	aterial	:	Chemical-resista	nt gloves
Re	emarks	:	Consider double	gloving.
Eye p	protection	:	If the work enviro mists or aerosols Wear a faceshiel	ses with side shields or goggles. Inment or activity involves dusty conditions, , wear the appropriate goggles. d or other full face protection if there is a ct contact to the face with dusts, mists, or
Skin a	and body protection	:	task being perfor posable suits) to	arments should be used based upon the med (e.g., sleevelets, apron, gauntlets, dis- avoid exposed skin surfaces. degowning techniques to remove potentially

Section 9: Physical and chemical properties

Appearance	:	Aqueous solution
Colour	:	Colorless to pale yellow
Odour	:	No data available
Odour Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available



Timolol Formulation

Versi 4.2	ion	Revision Date: 25.01.2024	-	S Number: 98363-00015	Date of last issue: 30.09.2023 Date of first issue: 01.05.2017
	Flamma	ability (solid, gas)	:	Not applicable	
	Flamm	ability (liquids)	:	No data available	9
		explosion limit / Upper bility limit	:	No data available)
		explosion limit / Lower bility limit	:	No data available	
	Vapour	pressure	:	No data available	9
	Relativ	e vapour density	:	No data available	
	Density	1	:	No data available)
	Solubili Wat	ty(ies) er solubility	:	soluble	
		n coefficient: n-	:	No data available	9
	octanol Auto-ig	/water nition temperature	:	No data available	
	Decom	position temperature	:	No data available)
	Viscosi Visc	ty cosity, kinematic	:	No data available)
	Explosi	ve properties	:	Not explosive	
	Oxidiziı	ng properties	:	The substance o	r mixture is not classified as oxidizing.
	Molecu	lar weight	:	Not applicable	
	Particle	e size	:	Not applicable	

Section 10: Stability and reactivity

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reac- tions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

Section 11: Toxicological information

Exposure routes



Timolol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	25.01.2024	1598363-00015	Date of first issue: 01.05.2017

Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Acute oral toxicity	:	LD50 (Rat): 1,000 mg/kg
		LD50 (Mouse): 1,140 mg/kg
Acute toxicity (other routes of administration)	:	LD50 (Mouse): 300 mg/kg Application Route: Intraperitoneal
		LD50 (Mouse): 800 mg/kg Application Route: Subcutaneous

Skin corrosion/irritation

Not classified based on available information.

Components:

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Species	:	Rabbit
Method	:	Draize Test
Result	:	No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Species Result	Rabbit Mild eye irritation
Species Result	Dog No eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.



Timolol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	25.01.2024	1598363-00015	Date of first issue: 01.05.2017

Chronic toxicity

Germ cell mutagenicity

Not classified based on available information.

Components:

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Method: OECD Test Guideline 471 Result: negative
Genotoxicity in vivo	:	Test Type: In vivo micronucleus test Species: Mouse Method: OECD Test Guideline 474 Result: negative

Carcinogenicity

Not classified based on available information.

Components:

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Species Application Route Exposure time LOAEL Result Target Organs Remarks		Rat Oral 2 Years 300 mg/kg body weight negative Adrenal gland The significance of these findings for humans is not certain.
Species Application Route Exposure time LOAEL Result Target Organs Remarks	:	Mouse, female Oral 18 Months 500 mg/kg body weight negative Lungs, Mammary gland, Uterus (including cervix) The significance of these findings for humans is not certain.
Carcinogenicity - Assess- ment	:	Weight of evidence does not support classification as a car- cinogen

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

(S)-3-[3-(tert-butylamino)-	2-hyd	roxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
Effects on fertility	:	Test Type: Fertility/early embryonic development

Encode on fording	Species: Rat
	Application Route: Oral
	Fertility: NOAEL Mating/Fertility: 150 mg/kg body weight



Timolol Formulation

	Revision Date: 25.01.2024		98363-00015	Date of last issue: 30.09.2023 Date of first issue: 01.05.2017
			Early Embryoni weight	c Development: NOAEL F1: 150 mg/kg body
Effect	s on foetal develop-	:	Test Type: Emb	oryo-foetal development
ment			Species: Rabbit Developmental	Toxicity: LOAEL F1: 50 mg/kg body weight vidence of adverse effects on development,
Repro sessm	ductive toxicity - As- nent	:	Some evidence animal experime	of adverse effects on development, based o ents.
стот	- single exposure			
	assified based on avail	lable	information.	
STOT	- repeated exposure			
	• •		o-vascular syste	m, Lungs) through prolonged or repeated ex
Produ	<u>ict:</u>			
	t Organs sment	:	Cardio-vascular Causes damage exposure.	system, Lungs to organs through prolonged or repeated
Comr	oonents:			
Comp				
		-hyd	roxypropoxy]-4	-morpholino-1,2,5-thiadiazole monomalea
(S)-3- Targe		e-hyd	Lungs, Cardio-v	-
(S)-3- Targe Asses	[3-(tert-butylamino)-2 t Organs	-hyd : :	Lungs, Cardio-v Causes damage	vascular system
(S)-3- Targe Asses Repea	[3-(tert-butylamino)-2 t Organs sment	e-hyd	Lungs, Cardio-v Causes damage	vascular system
(S)-3- Targe Asses Repea	[3-(tert-butylamino)-2 t Organs ssment ated dose toxicity ponents:	:	Lungs, Cardio-v Causes damage exposure.	vascular system to organs through prolonged or repeated
(S)-3- Targe Asses Repea	[3-(tert-butylamino)-2 t Organs ssment ated dose toxicity ponents: [3-(tert-butylamino)-2	:	Lungs, Cardio-v Causes damage exposure.	vascular system e to organs through prolonged or repeated
(S)-3- Targe Asses Repea <u>Comp</u> (S)-3- Specie NOAE	[3-(tert-butylamino)-2 t Organs ssment ated dose toxicity <u>ponents:</u> [3-(tert-butylamino)-2 es EL	:	Lungs, Cardio-v Causes damage exposure.	
(S)-3- Targe Asses Repea <u>Comp</u> (S)-3- Specie NOAE Applic	[3-(tert-butylamino)-2 t Organs ssment ated dose toxicity ponents: [3-(tert-butylamino)-2 es	:	Lungs, Cardio-v Causes damage exposure. roxypropoxy]-4- Rat	vascular system to organs through prolonged or repeated
(S)-3- Targe Asses Repea <u>Comp</u> (S)-3- Specie NOAE Applic	[3-(tert-butylamino)-2 t Organs sement ated dose toxicity ponents: [3-(tert-butylamino)-2 es EL sation Route sure time	:	Lungs, Cardio-v Causes damage exposure. roxypropoxy]-4 Rat 25 mg/kg Oral 67 Weeks	vascular system e to organs through prolonged or repeated
(S)-3- Targe Asses Repea Comp (S)-3- Specie NOAE Applic Expos	[3-(tert-butylamino)-2 t Organs sement ated dose toxicity <u>conents:</u> [3-(tert-butylamino)-2 es EL sation Route sure time es	:	Lungs, Cardio-v Causes damage exposure. roxypropoxy]-4 Rat 25 mg/kg Oral	vascular system to organs through prolonged or repeated
(S)-3- Targe Asses Repea Comp (S)-3- Specie NOAE Applic Specie NOAE Applic	[3-(tert-butylamino)-2 t Organs sement ated dose toxicity ponents: [3-(tert-butylamino)-2 es EL sation Route sure time es EL sation Route	:	Lungs, Cardio-v Causes damage exposure. roxypropoxy]-4- Rat 25 mg/kg Oral 67 Weeks Dog 10 mg/kg Oral Oral	vascular system to organs through prolonged or repeated
(S)-3- Targer Asses Repea Comp (S)-3- Specie NOAE Applic Expos Specie NOAE Applic Expos	[3-(tert-butylamino)-2 t Organs ssment ated dose toxicity <u>ponents:</u> [3-(tert-butylamino)-2 es EL sation Route sure time es	:	Lungs, Cardio-v Causes damage exposure. roxypropoxy]-4- Rat 25 mg/kg Oral 67 Weeks Dog 10 mg/kg	vascular system e to organs through prolonged or repeated

Aspiration toxicity

Not classified based on available information.



Timolol Formulation

2	Revision Date: 25.01.2024	SDS Nu 1598363		Date of last issue: 30.09.2023 Date of first issue: 01.05.2017
Exp	erience with human e	xposure		
-				
	<u>luct:</u> eral Information	Ston Resp	piratory dis ptoms: Irre	nal disorders orders gular cardiac activity, central nervous syste
Eye	contact			ning or stinging of the eye
<u>Com</u>	ponents:			
(S)-3	8-[3-(tert-butylamino)-	2-hydroxyp	propoxy]-4	-morpholino-1,2,5-thiadiazole monomale
Eye	stion	: Sym eyes libido : Sym troini	ptoms: bur , Headach o, hair loss ptoms: Hea testinal dis	ning or stinging of the eye, dryness of the e, Nausea, Dizziness, dry mouth, changes i , Allergic reactions adache, Fatigue, Respiratory disorders, Gas comfort, Allergic reactions, Rash, hair loss, status, Dizziness, changes in libido
	12: Ecological information	ation		
Eco	12: Ecological informatoxicity	ation		
Ecot <u>Com</u> (S)-3	toxicity	2-hydroxyp : LC50		-morpholino-1,2,5-thiadiazole monomale ales promelas (fathead minnow)): 411 mg/l 96 h
Ecot <u>Com</u> (S)-3 Toxid	t oxicity Iponents: B-[3-(tert-butylamino)- city to fish	2-hydroxyp : LC50 Expo er : EC50 Expo	0 (Pimepha osure time: 0 (Daphnia osure time:	ales promelas (fathead minnow)): 411 mg/l 96 h magna (Water flea)): 161 mg/l
Ecot <u>Com</u> (S)-3 Toxid Toxid aqua	toxicity aponents: B-[3-(tert-butylamino)- city to fish city to daphnia and othe	2-hydroxyp : LC50 Expo er : EC50 Expo Meth : EC50 Expo	0 (Pimepha osure time: 0 (Daphnia osure time: nod: OECD 0: > 1,000 osure time:	ales promelas (fathead minnow)): 411 mg/l 96 h magna (Water flea)): 161 mg/l 48 h Test Guideline 202 mg/l
Ecot <u>Com</u> (S)-3 Toxid Toxid aqua	aponents: B-[3-(tert-butylamino)- city to fish city to daphnia and other atic invertebrates	2-hydroxyp : LC50 Expo er : EC50 Expo Meth : EC50 Expo Test	0 (Pimepha osure time: 0 (Daphnia osure time: nod: OECD 0: > 1,000 osure time: Type: Res	ales promelas (fathead minnow)): 411 mg/l 96 h magna (Water flea)): 161 mg/l 48 h Test Guideline 202 mg/l 3 h
Ecot <u>Com</u> (S)-3 Toxid aqua	aponents: B-[3-(tert-butylamino)- city to fish city to daphnia and other atic invertebrates	2-hydroxyp : LC50 Expo er : EC50 Meth : EC50 Expo Test EC50	0 (Pimepha osure time: 0 (Daphnia osure time: nod: OECD 0: > 1,000 osure time: Type: Res	ales promelas (fathead minnow)): 411 mg/l 96 h magna (Water flea)): 161 mg/l 48 h Test Guideline 202 mg/l 3 h piration inhibition
Ecot <u>Com</u> (S)-3 Toxid aqua Toxid	aponents: B-[3-(tert-butylamino)- city to fish city to daphnia and othe atic invertebrates city to microorganisms	2-hydroxyp : LC50 Expo er : EC50 Meth : EC50 Expo Test EC50	0 (Pimepha osure time: 0 (Daphnia osure time: nod: OECD 0: > 1,000 osure time: Type: Res	ales promelas (fathead minnow)): 411 mg/l 96 h magna (Water flea)): 161 mg/l 48 h Test Guideline 202 mg/l 3 h piration inhibition
Ecot Com (S)-3 Toxid Toxid aqua Toxid Pers <u>Com</u> (S)-3	toxicity aponents: 3-[3-(tert-butylamino)- city to fish city to daphnia and other atic invertebrates city to microorganisms sistence and degradal	2-hydroxyp : LC50 Expo er : EC50 Meth : EC50 Test EC50 bility 2-hydroxyp : Resu Biod	0 (Pimepha osure time: 0 (Daphnia osure time: nod: OECD 0: > 1,000 osure time: Type: Res 0 (Photoba	<pre>ales promelas (fathead minnow)): 411 mg/l 96 h magna (Water flea)): 161 mg/l 48 h Test Guideline 202 mg/l 3 h piration inhibition cterium phosphoreum): > 1,800 mg/l -morpholino-1,2,5-thiadiazole monomale dily biodegradable. : 0 %</pre>



Timolol Formulation

/ersion 1.2	Revision Date: 25.01.2024	SDS Number: 1598363-00015	Date of last issue: 30.09.2023 Date of first issue: 01.05.2017
	ccumulative potentia	al	
<u>Com</u>	ponents:		
Partit	-[3-(tert-butylamino) tion coefficient: n- nol/water		-morpholino-1,2,5-thiadiazole monomaleate:
	i lity in soil ata available		
	r adverse effects ata available		
110 00			

Waste from residues	:	Do not dispose of waste into sewer.
		Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste han- dling site for recycling or disposal.
		If not otherwise specified: Dispose of as unused product.

Section 14: Transport information

International Regulations

UNRTDG	
--------	--

UN number Proper shipping name Class Subsidiary risk Packing group Labels	:	Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable
IATA-DGR UN/ID No. Proper shipping name Class Subsidiary risk Packing group Labels Packing instruction (cargo aircraft) Packing instruction (passen- ger aircraft)		Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable
IMDG-Code UN number Proper shipping name Class Subsidiary risk Packing group	· · · ·	Not applicable Not applicable Not applicable Not applicable Not applicable



Timolol Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
4.2	25.01.2024	1598363-00015	Date of first issue: 01.05.2017

Labels	:	Not applicable
EmS Code	:	Not applicable
Marine pollutant	:	Not applicable

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

NZS 5433		
UN number	:	Not applicable
Proper shipping name	:	Not applicable
Class	:	Not applicable
Subsidiary risk	:	Not applicable
Packing group	:	Not applicable
Labels	:	Not applicable
Hazchem Code	:	Not applicable

Special precautions for user

Not applicable

Section 15: Regulatory information

Safety, health and environmental regulations/legislation specific for the substance or mixture

HSNO Approval Number

HSR100425 Pharmaceutical Active Ingredients Group Standard

HSW Controls

Certified handler certificate not required. Tracking hazardous substance not required. Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

Section 16: Other information

Revision Date	:	25.01.2024
Further information		
Sources of key data used to compile the Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen- cy, http://echa.europa.eu/
Date format	:	dd.mm.yyyy



Timolol Formulation

Version R 4.2 2

Revision Date: 25.01.2024

SDS Number: 1598363-00015

Date of last issue: 30.09.2023 Date of first issue: 01.05.2017

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China: IMDG - International Maritime Dangerous Goods: IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN